Septerna (NASDAQ:SEPN) Stock Price Up 4.8% – Time to Buy?

Shares of Septerna, Inc. (NASDAQ:SEPN) were up 4.8% during mid-day trading on Wednesday . The stock traded as high as $24.11 and last traded at $24.11. Approximately 3,376 shares were traded during mid-day trading, a decline of 98% from the average daily volume of 203,363 shares. The stock had previously closed at $23.01.

Analyst Upgrades and Downgrades

SEPN has been the topic of several analyst reports. JPMorgan Chase & Co. began coverage on Septerna in a report on Tuesday, November 19th. They set an “overweight” rating and a $38.00 target price on the stock. Wells Fargo & Company began coverage on Septerna in a research report on Tuesday, November 19th. They issued an “overweight” rating and a $43.00 price objective on the stock. Cantor Fitzgerald assumed coverage on shares of Septerna in a report on Tuesday, November 19th. They set an “overweight” rating and a $50.00 target price for the company. Finally, TD Cowen started coverage on shares of Septerna in a report on Tuesday, November 19th. They set a “buy” rating on the stock.

Septerna Stock Performance

Insiders Place Their Bets

In other Septerna news, major shareholder Rock Ventures V. L.P. Third purchased 370,500 shares of the firm’s stock in a transaction dated Monday, October 28th. The shares were acquired at an average price of $18.00 per share, with a total value of $6,669,000.00. Following the purchase, the insider now directly owns 6,215,591 shares in the company, valued at approximately $111,880,638. This trade represents a 6.34 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.